ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE November 15, 2000

1 P.M. OPEN PUBLIC SPEAKERS (non-voting) and in order of speaking:

Overview of the ITFG/IPAC-RS Collaboration R. Harris Cummings, Ph.D.

Executive Director

Aerosol Product Development

Magellan Laboratories

P.O. Box 13341

Research Triangle Park, NC 27709 Email: RHCUMM@magellanlabs.com

BA/BE In Vitro and In Vivo Tests in Draft Guidance Lars Borgström, Ph.D.

> Scientific Adviser Experimental Medicine AstraZeneca R&D Lund S-22187 Lund, Sweden

Email: Lars.Borgstrom@AstraZeneca.com

Review of BA/BE Team's Responses to BA/BE Questions and Remaining Work

Lester I. Harrison, Ph.D. Senior Research Specialist 3M Pharmaceuticals

3M Center, Building 370-3S-05

St. Paul. MN 55144

Email: liharrison@mmm.com

Review of CMC Specifications Team's Submissions and Remaining Work (DCU/PSD)

Bo Olsson, Ph.D. Scientific Adviser

Microdrug Development AB

Sundbyvägen 24

645 51 Strägnäs, Sweden Email: Bo.Olsson@microdrug.nu

Description of Work of the Tests and Methods Team and Forthcoming Submissions

Carole Evans. Ph.D. Section Head

Magellan Laboratories P.O. Box 13341

Research Triangle Park, NC 277096) Email: cbevan@magellanlabs.com

Description of Work of the Leachables/Extractables Team, Supplier Quality Control Team and

Forthcoming Submissions Gordon Hansen

Associate Director

Research & Development Center

Boehringer Ingelheim 900 Ridgebury Road

Ridgefield, CT 068777-0368

Email: gehansen@rdg.boehringer-ingelheim.co

Concluding Presentation on ITFG/IPAC-RS Collaboration Cynthia L. Flynn, Ph.D.

Director, Worldwide Drug Product Pharmaceutical Quality Analysis

Aventis

500 Arcola Road Collegeville, PA 19426

Email: Cynthia.Flynn@aventis.com